Iovance Biotherapeutics (IOVA) closed at $7.76 on November 13, 2026, up 1.7% from the previous close, on volume of 10,807,758 shares (30-day average 13,985,433).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts | Position |
|---|---|---|---|---|---|
| 1 | Oct 29, 2026 | Call Spread | 15-Jan-2710 : 17 C | 15,030 | |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | ||||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Iovance Biotherapeutics to Present at Upcoming Conference
Globe Newswire (Thu, 12-Nov 4:05 PM ET)
ACCESS Newswire (Thu, 12-Nov 11:55 AM ET)
PRNewswire (Thu, 12-Nov 10:00 AM ET)
BrightSpring, Centene stand out as healthcare's most persistent Strong Buys
Seeking Alpha News (Thu, 12-Nov 7:38 AM ET)
Analysts Offer Insights on Healthcare Companies: Immutep (IMMP) and Iovance Biotherapeutics (IOVA)
TipRanks (Wed, 11-Nov 10:10 AM ET)
Iovance posts ~$122M record quarter as Amtagvi demand lifts gross margin to ~60%
Market Chameleon (Thu, 5-Nov 2:19 AM ET)
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Market Chameleon (Fri, 30-Oct 7:02 AM ET)
Globe Newswire (Thu, 29-Oct 7:00 AM ET)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Iovance Biotherapeutics trades on the NASDAQ stock market under the symbol IOVA.
As of November 13, 2026, IOVA stock price climbed to $7.76 with 10,807,758 million shares trading.
IOVA has a beta of 1.16, meaning it tends to be more sensitive to market movements. IOVA has a correlation of 0.02 to the broad based SPY ETF.
IOVA has a market cap of $3.46 billion. This is considered a Mid Cap stock.
Last quarter Iovance Biotherapeutics reported $121 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.04.
In the last 3 years, IOVA traded as high as $18.33 and as low as $1.64.
The top ETF exchange traded funds that IOVA belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.
IOVA has outperformed the market in the last year with a return of +222.0%, while the SPY ETF gained +13.4%. In the last 3 month period, IOVA beat the market returning +19.0%, while SPY returned -2.8%. However, in the most recent 2 weeks IOVA has underperformed the stock market by returning -8.5%, while SPY returned -0.2%.
IOVA support price is $7.15 and resistance is $8.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IOVA shares will trade within this expected range on the day.
